Zymeworks Inc. (NASDAQ:ZYME) Q2 2023 Earnings Call August 10, 2023 4:30 PM ET Company Participants Diana Papove - Director of Corporate Communications Chris Astle - Senior Vice President and Chief Financial Officer Kenneth Galbraith - Chair and Chief Executive Officer Paul Moore - Chief Scientific Officer Conference Call Participants Jon Miller - Evercore Yigal Nochomovitz - Citigroup Charles Zhu - Guggenheim Brian Cheng - JP Morgan Operator Thank you for standing by. This is the conference operator. Welcom ...

| --- | --- | --- | --- | --- | --- | |-------|-----------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | First Half 2023 Results | | | | | | | Conference Call and Webcast | | | | | | | | | | | | Forward-Looking Statements This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41535 __________________________ ...

Zymeworks Inc. (NASDAQ:ZYME) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Jack Spinks - Head of Investor Relations Chris Astle - Senior Vice President and Chief Financial Officer Kenneth Galbraith – Chairman and Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Charles Zhu - Guggenheim Partners Derek Archila - Wells Fargo Brian Cheng - JPMorgan Carly Kenselaar - Citi Phoebe Tan - Jefferies Operator Good day, and thank you for standing by. Welcome to ...

| --- | --- | --- | --- | --- | --- | |-------|-------|-----------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | First Quarter 2023 Results | | | | | | | Conference Call and Webcast | | | | | | | | | | | Forward-Looking Statements This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41535 _________________________ ...

Zymeworks Inc. (NASDAQ:ZYME) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Jack Spinks - Head of Investor Relations Chris Astle - Senior Vice President & Chief Financial Officer Kenneth Galbraith - Chair & Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citi James Shin - Wells Fargo Stephen Willey - Stifel Brian Cheng - JPMorgan Charles Zhu - Guggenheim Andrew Berens - SVB Leerink David Martin - Bloom Burton Operator Good day, ladies and gentlemen, a ...

| --- | --- | --- | --- | --- | |---------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | 4Q & FY 2022 Results Conference Call and Webcast | | | | | | March 7, 2023 | | | | | | Nasdaq: ZYME \| zymeworks.com | | | | | Forward-Looking Statements This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of applicable securities legislation, including Section 27A of the Securitie ...

Table of Contents 0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to ___________ Commission file number: 001-41535 _________________________ ZYMEW ...

| --- | --- | --- | --- | |---------------------------------------------------|-------|-------|-------| | | | | | | | | | | | SVB Securities Global | | | | | Biopharma Conference | | | | | Kenneth Galbraith Chair & CEO | | | | | Nasdaq: ZYME \| zymeworks.com February 14th, 2023 | | | | Legal Disclaimer 2 This presentation includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian secur ...